Program - Malmö Kongressbyrå

Transcript

Nordic Stroke 2015 18th Nordic Congress on Cerebrovascular Diseases 26-28 August 2015 • Malmö, Sweden PROGRAM www.nordicstroke.se Meaningful Change Together Medtronic trademarks are trademarks of a Medtronic company. COVIDIEN, COVIDIEN with logo and the Covidien logo are U.S. and CONTENTS CONTENTS Organisation for the 18th Nordic Congress on Cerebrovascular Diseases 3 Welcome to the 18th Nordic Congress on Cerebrovascular Diseases 5 General information 6 Social program 7 Exhibition area 8 Exhibitor list 9 Program 10-14 Posters 16-17 LOCAL ORGANISING COMMITEE SCIENTIFIC COMMITTEE Arne Lindgren (chair) Christina Brogårdh Irina Dragancea Ann-Cathrin Jönsson Bo Norrving Jesper Petersson Grethe Andersen, Denmark Eivind Berge, Norway Hanne Christensen, Denmark Per Olof Hansson, Sweden Bent Indredavik, Norway Dalius Jatuzis, Lithuania Janika Kõrv, Estonia Evija Miglane, Latvia Karsten Overgaard, Denmark Jukka Putaala, Finland Tiina Sairanen, Finland Katharina Stibrant Sunnerhagen, Sweden Per Wester, Sweden Mia von Euler, Sweden 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 3 EXPECT THE BEST OF ALL WORLDS FROM YOUR LEFT ATRIAL APPENDAGE OCCLUDER Patienters anatomi av vänster förmaksöra har alla tänkarbara former och storlekar precis som ett device för stroke-prevention bör ha. AMPLATZER™ Amulet™ left atrial appendage occluder är designad för komplett förslutning av öppningen till vänster förmaksöra med bättre kontroll och minimalt antal steg. Den proximala positioneringen med flexibel nitinol design syftar till att passa olika LAA storlekar och kan repositioneras eller återhämtas vilket krävs för optimal placering. Besök www.sjm.com/Amulet för att lära mer om hur AMPLATZER™ teknologin gör Amulet devicet det självklara valet för LAA occlusion. CAUTION: Device not available in the United States. Product referenced is approved for CE Mark. Device depicted may not be available in all countries. Check with your St. Jude Medical representative for product availability in your country. Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. and its related companies. © 2014 St. Jude Medical, Inc. All Rights Reserved. EM-AMU-0215-0015 | This document is for international use only. WELCOME Dear friends and colleagues, On behalf of the organising committee and the Nordic Stroke Society, it is my great pleasure to welcome all of you to the 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August 26-28, 2015. Also a great welcome to our friends and colleagues from Korea who have successfully contributed and participated in the past Nordic Congresses and continue to take an active part in our Congress. Since the previous, very successful meeting in Vilnius, Lithuania in 2013, numerous new advances have been made within the cerebrovascular field including prevention, acute stroke care, post stroke care, rehabilitation and basic sciences. It is therefore very timely for us to meet in Malmö and discuss and update our opinion on how these new advances affect the clinical everyday situation from a Nordic viewpoint. The program is exciting and covers most perspectives on cerebrovascular disease. We are very happy that we have been able to include so many valuable and important up-to date presentations on stroke with many well-known international experts on stroke. You will all have the opportunity to take part in plenary sessions, workshops, free communications, a poster session as well as social events. In August the Nordic summer usually offers a delightful weather and before and after the conference, there are good opportunities to discover the wonderful nature and cultural sights of nearby areas in Sweden and Denmark including the University town of Lund and Copenhagen. The Nordic Congress on Cerebrovascular Disease has a history of being warm and welcome and providing excellent opportunities to exchange and obtain knowledge and experience on stroke and cerebrovascular diseases. We in the organising committee will do our very best to continue this tradition of a combination of hospitality, friendship and science and look very much forward to a successful conference in Malmö. We hope you will enjoy the Congress and wish you a very pleasant stay in Malmö. Warmly welcome to the 18th Nordic Congress on Cerebrovascular Diseases, Arne Lindgren Chair of the 18th Nordic Congress on Cerebrovascular Diseases 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 5 GENERAL GENERAL INFORMATION INFORMATION NAME BADGE Name badge must be worn at all times during the congress to ensure access to all sientific sessions and the exhibition area. MEALS Coffee and lunch breaks are included in the the registration fee and will be provided within the exhibition area. INTERNET Free access for all delegates in the congress area with the network ”Malmömässan Open”. POSTER VISIT Poster visit 27th of August at 15.30-16.15. SPEAKERS SERVICE CENTER Give your presentation to the technician in speakers service center in room 5. Preferably in the morning of the day of your talk, but no later than two hours before your presentation. MOBILE PHONES Mobile phones must be in silent mode during the sessions. TAXI Taxi Skåne Taxi Kurir +46 (0)40 330 330 +46 (0)40 70 000 VENUE Malmö Mässan Mässgatan 6 215 32 Malmö, Sweden CONFERENCE AGENCY During the conference you will find staff from Malmö Conference Agency at the registration desk. Project Manager Ola Nilsson [email protected] +46 733 20 20 10 6 Hotels & Delegates Sofie Welander [email protected] +46 729 75 26 22 Malmö Kongressbyrå (PCO) Norra Vallgatan 16 211 25 Malmö, Sweden www.mkon.se 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 SOCIAL PROGRAM WELCOME RECEPTION Welcome to the the exhibition area at Malmö Mässan. You will be served a light meal with beverages. Pre registration is required. When: 26th of August, at 19.30 Dresscode: Informal CONGRESS DINNER In the most beautiful parts of Malmö you will find our restaurant Glasklart. You will be served a three course dinner. The spectacular venue has a ceiling height of 38 meter and a glass facade towards the sea. Observe, non alcoholic drinks are included in the fee. Alcoholic beverages can be purchased during the welcome drink. To attend the dinner, pre registration is required. When: 27th of August, at 19.30 Where: Glasklart, Dockplatsen 1, Malmö Dresscode: Jacket/Semi Formal Buses from & to Glasklart: Leave from Malmö Mässan (address, Mässgatan 6, Malmö) at 19:15. Return from Glasklart to Malmö Mässan at 22.15 and 22.45. 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 7 Hyllie Vattenparksgata EXHIBITON AREAAREA & FLOOR PLAN EXHIBITION Hyllie Trainstation 8 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 EXHIBITOR LIST NUMERICAL ORDER 1 Stryker 2 Scandinavian Medical Sweden AB 3 St. Jude Medical Sweden AB 4 Covidien Sverige AB a Medtronic Company 5 Boehringer Ingelheim AB 6 Bayer AB 7 CampScandinavia AB 8 EPS Vascular AB 9 Neuravi 10 Zenicor Medical Systems AB 11 Ottobock Scandinavian Group 12 Pfizer and Bristol-Myers-Squibb 13 SITS International 14 Effects-studien 15 Embreis AB ALPHABETICAL ORDER Bayer AB Boehringer Ingelheim AB CampScandinavia AB 6 5 7 Covidien Sverige AB a Medtronic Company 4 Effects-studien 14 Embreis AB 15 EPS Vascular AB 8 Neuravi 9 Ottobock Scandinavian Group 11 Pfizer and Bristol-Myers-Squibb 12 Scandinavian Medical Sweden AB 2 SITS International 13 St. Jude Medical Sweden AB 3 Stryker 1 Zenicor Medical Systems AB 10 EXHIBITON & FLOOR26 PLAN PROGRAM -AREA WEDNESDAY AUGUST Sal 1 09.00-10.45 Registration 10.45-11.00 Welcome Address Arne Lindgren, Lund Dalius Jatuzis, Vilnius 11.00-12.30 Plenary session Endovascular therapy in acute ischemic stroke Chairs: Nils Wahlgren, Stockholm; Arne Lindgren, Lund Current evidence from randomised trials (20 + 2 min) Heinrich Mattle, Bern Techniques for endovascular treatment (10 + 2 min) Staffan Holmin, Stockholm The Aarhus experience of endovascular therapy (10 + 2 min) Grethe Andersen, Aarhus The roadmap for implementation of endovascular stroke therapy in Sweden (10 + 2 min) Nils Wahlgren, Stockholm What’s special about basilar artery occlusion? (10 + 2 min) Perttu Lindsberg, Helsinki General discussion (20 min) 12.30-14.00 Lunch Satellite symposium 12.55-13.55 Stroke prevention challenges in AF Sponsored by St. Jude Medical Chair: Mårten Rosenqvist, Stockholm; Derk W. Krieger, Copenhagen AF and stroke – current knowledge and future challenges (18 + 2 min) Per Wester, Umeå Use of antithrombotics among ICH survivors (18 + 2 min) Sören Paaske Johnsen, Aarhus Left Atrial Appendage Occlusion after ICH (18 + 2 min) Jens Erik Nielsen Kudsk, Aarhus 14.00-15.30 Plenary session Joint Session of the Korean and Nordic Stroke Societies on Intracerebral Hemorrhage Chairs: Byung-Chul Lee, Seoul; Mia von Euler, Stockholm Epidemiology and risk factors for ICH in Asian and European populations (13 + 2 min) Hee-Joon Bae, Seoul How to investigate patients with ICH? (13 + 2 min) Mia von Euler, Stockholm BP management and ICH (13 + 2 min) Hyung-Min Kwon, Seoul Surgical management of spontaneous ICH from a Korean perspective (13 + 2 min) Jeong Eun Kim, Seoul Surgical management of spontaneous ICH from a Nordic perspective (13 + 2 min) Ola G Nilsson, Lund General discussion (15 min) 10 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 PROGRAM - WEDNESDAY 26 AUGUST Sal 2 Sal 1 Sal 3 15.30-16.00 Coffe break 16.00-17.30 Teaching course 1 Free communications Chairs: Grethe Andersen, Chairs: Markku Aarhus; Per Wester, Umeå Kaste, Helsinki O01 - A follow-up on persons Thrombolysis: 5 years after subarachnoid Which patients hemorrhage (10 + 5 min) should be Lovisa Carlsson, Göteborg treated? O02 - Diabetes Mellitus and (40 + 5 min) Peter Sandercock, Spontaneous Intracerebral Hemorrhage: Clinical Edinburgh Features and Mortality (10 + 5 min) Stroke mimics Ron Liebkind, Helsinki (40 + 5 min) Heinrich Mattle, O03 - High sensitivity-CRP Bern a bio-marker in stroke sub-types? (10 + 5 min) Lotta Larsson, Herlev O04 - Clinical genetic testing for monogenic ischemic stroke in the age of next generation sequencing (10 + 5 min) Andreea Ilinca, Malmö O05 - Outcome and complications after iv. thrombolysis in women and men over 80 (10 + 5 min) Christine Kremer, Malmö O06 - Etiology of ischemic stroke in young Estonian patients (10 + 5 min) Janika Kõrv, Tartu Workshop: Stroke rehabilitation Chairs: Christina Brogårdh, Lund; Bent Indredavik, Trondheim A comparison of stroke rehabilitation in Latvia and Sweden (20 + 4 min) Guna Berzina, Riga Home-based rehabilitation for stroke inpatients can reduce disability and improve quality of life (20 + 4 min) Rune Skovgaard Rasmussen, Copenhagen Early Supported Discharge: outcomes, organization and cost effectiveness (20 + 4 min) Lena von Koch, Stockholm Importance of maintaining exercise and training after stroke (20 + 4 min) Birgitta Langhammer, Oslo Sal 1 17.35-18.35 Satellite symposium: Recent advances in stroke therapy Sponsored by Medtronic Chair: Nils Wahlgren, Stockholm Intermittent Pneumatic Compression for DVT prevention – the CLOTS3 trial (18 + 2 min) Peter Sandercock, Edinburgh Acute ischemic Stroke, Endovascular Treatment Update following the recent clinical data (18 + 2 min) Tommy Andersson, Stockholm Detection and Evaluation of ”silent” Atrial Fibrillation in Patients with Cryptogenic Stroke (18 + 2 min) Derk Krieger, Copenhagen 19.00-21.00 Welcome reception and exhibition at Malmö Mässan 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 11 EXHIBITON & FLOOR27PLAN PROGRAMAREA - THURSDAY AUGUST Sal 1 Sal 3 08.30-10.00 Free communications Chairs: Per Olof Hansson, Gothenburg; Christine Kremer, Malmö O07 - Quantitative Interpretation of White Matter Hyperintensity Using Statistical Maps (10 + 5 min) Dong-Eog Kim, Goyang O08 - Reproducibility of repeated endothelial function measurements using a digital plethysmographic technique (10 + 5 min) Aina Støttrup Hansen, Herlev O09 - The value of arterial transit artifact with arterial spin labeling MRI in patients with internal carotid artery stenosis (10 + 5 min) Hyunkoo Kang, Seoul O10 - Treatment of fatigue after stroke with modafinil - a randomized, placebo controlled trial. (10 + 5 min) Mai Bang Poulsen, Herlev O11 - Motor function recovery in patients with ischemic versus hemorrhagic stroke during the first year (10 + 5 min) Hanna Persson, Göteborg O12 - Work-aged stroke survivors’ short time and long term psychosocial challenges and follow-up needs (10 + 5 min) Randi Martinsen, Elverum 10.00-10.30 Workshop: Stroke in the young Chairs: Jukka Putaala, Helsinki; Halvor Naess, Bergen Ischemic stroke risk factors and subtypes in the young (20 + 4 min) Jukka Putaala, Helsinki Uncommon causes, how to identify and diagnose (20 + 4 min) Katarina Jood, Gothenburg Stroke in the young from an East Asian perspective (20 + 4 min) Jong Sung Kim, Seoul Prognosis and long term outcome (20 + 4 min) Halvor Naess, Bergen Coffe break Sal 1 10.30-12.00 Plenary session Current situation in Acute stroke care and TIA management in the Nordic Countries Chairs: Sören Paaske Johnsen; Aarhus; Bo Norrving, Lund Denmark (Sören Paaske Johnsen, Aarhus) (13 + 2 min) Finland (Tiina Sairanen, Helsinki) (13 + 2 min) Norway (Bent Indredavik, Trondheim) (13 + 2 min) Sweden (Bo Norrving, Lund) (13 + 2 min) Lithuania (Dalius Jatusiz, Vilnius) (13 + 2 min) General discussion (15 min) 12.00-12.30 General assembly of Nordic Stroke Society 12.30-14.00 Lunch Satellite symposium: 12:55-13:55 New advances in OAC treatment in AF Sponsored by Boehringer Ingelheim Chairs: Ann-Charlotte Laska, Stockholm; Pyotr Platonov, Lund Acute management of stroke during OAC therapy (30 + 3 min) Karin Klijn, Nijmegen Emergency treatment of ICH during OAC treatment (15 +2 min) Dorte Damgaard, Aarhus General discussion (10 min) 12 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 PROGRAM - THURSDAY 27 AUGUST Sal 2 14.00-15.30 Teaching course 2 Sal 1 Free communications Chairs: Bo Norrving, Lund Chairs: Bent Indredavik, Trondheim; Tiina Sairanen, Helsinki Brainstem syndromes O13 - Warfarin persistence (40 + 5 min) among atrial fibrillation Jong Sung Kim, Seoul patients - why is treatment ended? (10 + 5 min) Fredrik Björck, Sundsvall Transcranial Color-Coded Duplex O14 - Acute Intensive Sonography- an Blood Pressure-Lowering Treatment in Patients with introduction and overview (20 + 2 min) Intracerebral Hemorrhage (10 + 5 min) Christine Kremer, Juliane Zickert, Aarhus Malmö O15 - Improving logistics for acute ischaemic stroke TCCS monitoring of (10 + 5 min) systemic thrombolysis treatment Claus Z. Simonsen, Aarhus in acute stroke O16 - Concurrent Holter (20 + 3 min) monitoring and thumbFabienne Perren, ECG for detection of Géneve atrial fibrillation in stroke patients- which is best? (10 + 5 min) Mai Bang Poulsen, Herlev O17 - Predictors of Clinical Outcome in Ischemic Stroke Patients Treated With Intravenous Thrombolysis Based on Magnetic Resonance Imaging (10 + 5 min) Marie Louise Schmitz, Aarhus 15.30-16.15 16.15-17.30 19.30- Sal 3 Workshop: Team based stroke care Chairs: Ann Cathrin Jönsson, Lund; Susanne Zielke Schaarup, Copenhagen Initial nursing assessment and monitoring in stroke care (20 + 4 min) Susanne Zielke Schaarup, Copenhagen Eating difficulties and nutrition after stroke (20 + 4 min) Albert Westergren, Kristianstad Balance and cognition post-stroke (20 + 4 min) Marie H. Ursin, Oslo Driving assessment after stroke (20 + 4 min) Helena Selander, Göteborg Coffe break and Poster visit Sal 1 Plenary session Stroke recovery and prognosis Chairs: Janika Kõrv, Tartu; Katharina Stibrant Sunnerhagen, Göteborg Outcome, prognosis (15 + 2 min) Jannika Kõrv, Tartu Experimental recovery studies (15 + 2 min) Tadeusz Wieloch, Lund New rehabilitation methods (15 + 2 min) Katharina Stibrant Sunnerhagen, Göteborg Pharmacological treatment overview and special emphasis on SSRI treatment (15 + 2 min) Janne Keergard Mortensson, Aarhus General discussion (7 min) Dinner at Glasklart Bus transport at 19.15 from Malmö Mässan. Return from Glasklart to Malmö Mässan at 22.15 and 22.45. 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 13 EXHIBITON AREA & FLOOR PLAN PROGRAM - FRIDAY 28 AUGUST Sal 1 08.30-10.00 Free communications Chairs: Evija Miglane, Riga; Katharina Stibrant Sunnerhagen, Göteborg O18 - The Shape/Texture Identification test (STItestTM): a reliable measure of active touch after stroke (10 + 5 min) Elisabeth Ekstrand, Malmö O19 - Basic body awareness therapy in persons with stroke: experiences among patients and physiotherapists (10 + 5 min) Mialinn Arvidsson Lindvall, Örebro O20 - A multicenter study on transfer, walking and stair climbing in persons with stroke (10 + 5 min) Birgitta Langhammer, Oslo O21 - New aerob exercise test: Good in stroke? (10 + 5 min) Rikke Steen Krawcyk, Herlev O22 - Promoting psychosocial wellbeing following stroke using narratives and guided self-determination: a feasibility study (10 + 5 min) Marit Kirkevold, Oslo O23 - Long-term predictors for participation in social and leisure activities ten years after stroke. (10 + 5 min) Anna Norlander, Lund 10.00-10.30 Coffe break Sal 3 Workshop: Ischemic stroke risk factors and secondary prevention Chairs: Eivind Berge, Oslo; Per Wester, Umeå Carotid artery disease (20 + 4 min) Per Wester, Umeå Risk factors (20 + 4 min) Riina Vibo, Tartu Secondary prevention (20 + 4 min) Eivind Berge, Oslo Small vessel disease (20 + 4 min) Susanna Melkas, Helsinki Sal 1 10.30-12.00 Plenary session Heart and brain: Diagnosis and management Chairs: Hanne Christensen, Copenhagen; Jesper Petersson, Lund Diagnostics and monitoring (15 + 2 min) Hanne Christensen, Copenhagen Secondary prohylaxis following cardiac causes of stroke (15 + 2 min) Karsten Overgaard, Copenhagen Stroke in patients treated with NOAC or Warfarin (15 + 2 min ) Jesper Petersson, Lund Anticoagulation to AF patients with ICH on OAC treatment (7 + 2 min) Karin Klijn, Nijmegen Heart and cryptogenic stroke (15 + 2 min) Arne Lindgren, Lund General discussion (13 min) 12.00-12.30 Nordic stroke award lecture Treatment of Acute Ischaemic Stroke: We are - perhaps - at the end of the beginning Nils Wahlgren, Stockholm 12.30-12.45 Farewell Arne Lindgren, Lund New incoming congress representatives TBD Dalius Jatuzis, Vilnius 12.45Lunch grab and go 14 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 Quality for life Vi har haft som mission under nio decennier att hjälpa människor att återställa och förbättra sin rörlighet och självständighet. Utifrån ett noggrant kvalitetsarbete, avancerad teknik och nära samarbeten med patienter, sjukvård och branschorganisationer vill vi bidra till ett samhälle med fokus på livskvalitet. För alla. Via vårt dotterbolag Aktiv Ortopedteknik driver vi idag ortopedtekniska center över hela Sverige. Vi tar emot landstingspatienter såväl som privatpersoner som är i behov av hjälpmedel för en aktivare vardag. Välkommen. ottobock.se Till patienter med icke-valvulärtförmaksflimmer: Xarelto® 15/20 mg – enda NOAK där produktresumé på Fass.se ger stöd för både initiering och fortsatt behandling vid KON RTERING Xarelto (rivaroxaban), antitrombotiskt medel, ℞ (B01 AF01). Tabletter 15 mg, 20 mg. Indikationer: 15 mg och 20 mg: Förebyggande av stroke och systemisk embolism hos vuxna patienter med icke-valvulärt förmaksflimmer med en eller flera riskfaktorer, såsom hjärtsvikt, hypertoni, ålder ≥ 75 år, diabetes mellitus, tidigare stroke eller transitorisk ischemisk attack (F). Behandling av djup ventrombos (DVT) och lungemboli (LE), och förebyggande av återkommande DVT och LE hos vuxna (F). Dosering: Förebyggande av stroke och systemisk embolism: rekommenderad dos är 20 mg en gång dagligen, vilket också är den rekommenderade maxdosen. Behandling av DVT och LE och förebyggande av återkommande DVT och LE: rekommenderad dos för initial behandling av akut DVT eller LE är 15 mg två gånger dagligen under de första tre veckorna, följt av 20 mg en gång dagligen för fortsatt behandling och förebyggande av återkommande DVT och LE. Särskilda patientpopulationer: För patienter med måttligt (kreatininclearance 30–49 ml/min) eller svårt (kreatininclearance 15–29 ml/min) nedsatt njurfunktion gäller följande doseringsrekommendationer: Vid förebyggande av stroke och systemisk embolism hos patienter med icke-valvulärt förmaksflimmer är den rekommenderade dosen 15 mg en gång dagligen. Vid behandling av DVT och LE och förebyggande av återkommande DVT och LE: patienterna ska behandlas med 15 mg två gånger dagligen under de första tre veckorna. Därefter är den rekommenderade dosen 20 mg en gång dagligen. En sänkning av dosen från 20 mg en gång dagligen till 15 mg en gång dagligen bör övervägas om patientens risk för blödning bedöms överstiga risken för återkommande DVT och LE. Patienter med förmaksflimmer som genomgår konvertering: Behandling med Xarelto kan initieras eller fortskrida hos patienter som kan behöva konvertering. Kontraindikationer: Överkänslighet mot den aktiva substansen eller mot något hjälpämne som anges i avsnitt 6. Aktiv, kliniskt signifikant blödning. Organskada eller tillstånd, som anses utgöra en ökad risk för större blödning. Detta kan omfatta pågående eller nyliga ulcerationer i magtarmkanalen, förekomst av maligna tumörer med hög blödningsrisk, nyliga hjärn- eller ryggradsskador, nyligen genomgången hjärn-, ryggrads- eller ögonkirurgi, nyligen genomgången intrakraniell blödning, kända eller misstänkta esofagusvaricer, arteriovenösa missbildningar, vaskulära aneurysm eller större intraspinala eller intracerebrala vaskulära missbildningar. Samtidig behandling med andra antikoagulantia, t.ex. ofraktionerat heparin (UFH), lågmolekylärt heparin (enoxaparin, dalteparin etc.), heparinderivat (fondaparinux etc.), orala antikoagulantia (warfarin, dabigatranetexilat, apixaban etc.), förutom vid byte av behandling till eller från rivaroxaban eller när UFH ges i doser som krävs för att hålla en central ven- eller artärkateter öppen. Leversjukdom förknippad med koagulopati och kliniskt relevant blödningsrisk inklusive cirrotiska patienter med Child Pugh B och C. Graviditet och amning. Varningar och försiktighet: Xarelto ska användas med försiktighet hos patienter med kreatininclearance 15–29 ml/min. Användning av Xarelto hos patienter med kreatininclearance < 15 ml/min rekommenderas inte. Hos flera undergrupper av patienter föreligger en ökad blödningsrisk. Dessa patienter ska övervakas noga för tecken på blödningskomplikationer efter att behandlingen inletts. För fullständig information om varningar och försiktighet var god se www.fass.se. Förpackningar och förmån: 15 mg: 28 tabl. (F), 42 tabl. (F), 98 tabl. (F), 100 tabl. (F). 20 mg: 28 tabl. (F), 98 tabl. (F), 100 tabl. (F). För ytterligare information och prisuppgift var god se www.fass.se. Datum för senaste översynen av produktresumén juli 2015. Bayer AB. Box 606. 169 26 Solna. Tel. 08-580 223 00. ▼ Detta läkemedel är föremål för utökad övervakning. L.SE.03.2015.1598 POSTERS Poster number and titel Poster visit on August 27, at 15.30-16.15 P01 - Reducing Stroke Door-To-Needle Time Peter O’Keeffe, London P02 - Predict value of circulating vascular endothelial growth factor-1 in hypertensive patients after acute ischemic stroke Alexander Berezin, Zaporozhye P03 - Polymorphisms in the serotonin transporter gene and the risk of stroke –an association study. Janne Kaergård Mortensen, Aarhus P04 - Cardiovascular risk factors and TIA characteristics in 19,872 Swedish TIA patients Jakob Ström, Örebro P05 - Pre-stroke characteristics and stroke severity after first stroke in middle-aged men Cecilia Bergh, Örebro P06 - Risk factors and imaging characteristics of acute lacunar infarct and associated features of small vessel disease in brainstem and cerebellum Eufrozina Selariu, Malmö P07 - The role and action of phosphodiesterase 3 in cerebral small vessel disease Saiqa Yasmeen, Herlev P08 - Hyperintense vessel signal on arterial spin labeling MR image in acute ischemic stroke Dong Woo Park, Guri P9 - Arterial spin labeling perfusion MRI for acute territorial infarct, compared with dynamic susceptibility contrast-enhanced perfusion MRI Dong Woo Park, Guri P10 - Stroke Forum – a link between hospital and society Katharina Stibrant Sunnerhagen, Gothenburg P11 - The system organization of control in the outpatient clinics for the secondary prevention measures of the patients after stroke in the post-hospital stage in the separately taken industrial area with a population of over 500,000 Naberezhnye Chelny, Tatarstan, Russia Alfiya Godunova, Naberejnye Chelny P12 - Incidence of Transient Ischemic Attacks in Sweden during 2011-2012. A study based on Riksstroke’s TIA register. Peter Appelros, Örebro P13 - The Involving Ward Round Lone Lundbak Mathiesen, Glostrup 16 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 POSTERS P14 - Transient global amnesia after upper GI endoscopy without premedication: two cases reports. Won Tae Yoon, Seoul P15 - Intensive treadmill training in the acute phase after ischemic stroke and standardized activities in TIA patients measured by accelerometry Thomas Christensen, Hillerød P16 - Twenty years trends in mortality rate from stroke in Klaipeda Rima Radziuviene, Palanga P17 - Swedish version of Post-Stroke Checklist (PSC-S) Emma Kjörk, Gothenburg P18 - Gothenburg Very Early Supported Discharge (GOTVED) - mapping of exclusion and dropout Lena Rafsten, Gothenburg P19 - Grip strength is strongly associated with upper extremity muscle weakness after stroke Christina Brogårdh, Lund P20 - Measurement variability of Quantitative Sensory Testing in persons with shoulder pain after stroke Ingrid Lindgren, Lund P21 - Movement deficits in the ipsilesional “less-affected” upper extremity after stroke. Stroke Arm Longitudinal study at Gothenburg University, SALGOT-study. Eva-Lena Bustrén, Gothenburg P22 - Locked-in syndrome in Sweden; An explorative study of persons who underwent rehabilitation Kajsa Svernling, Gothenburg P23 - Promoting psychosocial wellbeing in persons with aphasia - a feasibility study Berit A. Bronken, Elverum P24 - Exploration of potential relationship between casemix-adjusted levels of good functional outcomes and total inpatient days during first year after stroke in Sweden - Results from Sveus Ingrid Lekander, Stockholm P25 - Casemix-adjusted comparisons of health outcomes and resource utilization first year following a stroke in Sweden – Results from Sveus Ingrid Lekander, Stockholm P26 - RISCLON - Risk of Recurrent Stroke in Clopidogrel Non-responders Charlotte Lützhøft Rath, Roskilde P27 - Mitral E/A Ratio and Potential-Cardioembolic Stroke Kim Yerim, Gyeonggido 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 17 NOTES The aim of the Nordic Stroke Society is to promote research on cerebrovascular disorders in the Nordic and Baltic countries with special emphasis on scientific collaboration and exchange across national borders and between professional disciplines. The Society was founded in 1982 under the name Scandinavian Society for Cerebrovascular Diseases. In 2005 the name was changed to Nordic Stroke Society, and colleagues from the Baltic countries were formally welcomed to the organisation. It is now the oldest of the regional stroke organisations in Europe. www.nordicstroke.org 18 18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015 • Over 4 years of real world experience1 • An FDA confirmed safety and efficacy profile2 PRADAXA® – LIVES UP TO THE PROMISE3, 4 What does this mean for your next new AF patient? CV-15-55 Referenser: 1. FDA 19 okt 2010: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. 2. Graham DJ, et al. Circulation 2015;131(2):157–64. 3. Connolly SJ, et al. N Eng J Med 2009;361:1139–51 [Erratum: N Eng J Med 2010;363:1875–6 and N Eng J Med 2014;371(15):1464–5]. 4. Larsen TB, et al. Am J Med 2014;127(7):650–6. Prescribing information: Pradaxa® (dabigatran etexilate), anticoagulant, Rx, F. Indications: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Strengths and packages: 60 x 1 and multipack 3 x 60 x 1, blister. Capsules 110 mg and 150 mg. Warnings and restrictions: Renal function should be assessed prior to initiation of treatment with Pradaxa. Pradaxa should be used with caution in patients with a history of/known risk factors for myocardial infarction. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Patients with severe renal impairment (CrCL <30 ml/ min). Active clinically significant bleeding. Lesion or condition, if considered a significant risk factor for major bleeding. Spontaneous or pharmacological impairment of haemostasis. Hepatic impairment or liver disease expected to have any impact on survival. Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole and dronedarone. Prosthetic heart valves. For price and other information please see www.fass.se. Date of revision of the SPC 12/2014. Boehringer Ingelheim AB. Box 47608, SE 117 94 Stockholm, Sweden. Phone +46 (0)8-721 21 00. Fax +46 (0)8-710 98 84. www.boehringer-ingelheim.se Thank’s to our sponsors and exhibitors GOLD SPONSORS SPONSORS EXHIBITORS